1. Bayh-Dole Act. Pub L 96-517, 37 CFR §401> (1980).
2. PHS Objectivity in Research, 42 CFR 50.601 et seq, 60 FR 35815, July 11, 1995; Responsible Prospective Contracts, 45 CFR Part 94, 60 FR 35817, July 11, 1995; FDA Financial Disclosure by Clinical Investigators, 21 CFR Part 54, 63 FR 5250, February 2, 1998.
3. Guidelines for interactions between clinical faculty and the pharmaceutical industry: one medical school's approach;Coleman;Acad Med,2006